[Press release] A national survey on sleep quality to better prevent neurodegenerative diseases
The National Centre of Excellence in Research on Parkinson’s Disease (NCER-PD) launches a nation-wide research survey on sleep behaviour disorders under the patronage of the Ministry of Health.
Understanding the impact of dietary fibres on the gut microbiome
On February 9th, Erica Grant, doctoral candidate within the Eco-Immunology and Microbiome group of the LIH Department of Infection and Immunity (DII), was awarded the 2020 Pelican Grant by the Fondation du Pélican de Mie et Pierre Hippert-Faber. The grant will support her training and mobility activities in the context of her research project on the gut microbiome.
LUX:plorations comics: explaining science through art!
Several PhD candidates from the LIH Departments of Infection and Immunity (DII), Population Health (DoPH) and Oncology (DONC) contributed to “LUX:plorations”, an innovative series of catchy cartoons promoted by the Doctoral Education in Science Communication (DESCOM) project of the University of Luxembourg. The aim of the initiative? Explaining science and research to the lay public in a colourful and artistic way!
[Press release] COVID-19: mass screening reveals significant transmission risk from asymptomatic carriers
Based on the results of the large-scale testing programme run in Luxembourg, researchers show that asymptomatic SARS-CoV-2 carriers represent an important vector for transmission.
Towards personalised treatment of recurrent brain tumours
On February 25th, Prof Simone Niclou, Director of the LIH Department of Oncology (DONC) and group leader of the NORLUX Neuro-Oncology Laboratory, was awarded a EUR 850,000 check by the Fondation Cancer and the Luxembourg National Research Fund (FNR) in support of the GLASS-LUX study.
Important support to LIH cancer research
On February 25th, three LIH group leaders from the Department of Oncology (DONC) were awarded a symbolic check by the Fondation Cancer and the Luxembourg National Research Fund (FNR) in support of their cancer research projects.
Hypertension: know what is behind your numbers
High blood pressure (HBP) or hypertension is often called the ‘‘silent killer’’, due to the lack of obvious symptoms indicating its presence. It is therefore important to be able to self-monitor one’s blood pressure and understand how to interpret the measurements. To this end, the Cardiovascular Research Unit (CVRU) of the LIH Department of Population Health (DoPH) recently published an informative brochure to help shed light into cardiovascular health.
Industrial partnerships with Pharma to strengthen translational research at LIH
The Tumor Immunotherapy and Microenvironment (TIME) research group of the LIH Department of Oncology (DONC) teamed up with Swedish Pharma company Sprint Bioscience to investigate the therapeutic benefit of small molecules inhibiting key pathways in cancer cells. The aim is to potentiate the effectiveness of immunotherapy and providing innovative and translational approaches to treating several cancers.
[Press release] Novel immunotherapy approach to treat cat allergy
Researchers from the Department of Infection and Immunity of the Luxembourg Institute of Health (LIH) brought forward the potential of high doses of a specific adjuvant molecule, namely CpG oligonucleotide, in successfully modulating the immune system’s allergic response to the main cat allergen Fel d 1, thereby inducing a tolerance-promoting reaction and reverting the main hallmarks of cat allergy. The researchers analysed the molecular mechanisms underlying this tolerance and proposed a pre-clinical allergen-specific immunotherapy approach to improve the treatment and control of this common type of allergy. The full study results were published very recently in the renowned international journal “Allergy”, the official journal of the European Academy of Allergy and Clinical Immunology (EAACI) and one of the top two journals worldwide in the allergy field.